Dr. G.S.K. Velu, Chairman of Trivitron Healthcare, attended a special luncheon hosted by the Hon'ble Prime Minister of India, Shri Narendra Modi, on October 5, 2026, in honour of His Excellency Mr. Guy Parmelin, President of the Swiss Confederation, and Mrs. Dominique Parmelin. The luncheon, held at Hyderabad House in New Delhi, brought together distinguished representatives and highlighted the growing relationship between India and Switzerland.
The occasion was particularly meaningful to us, bringing together an important diplomatic engagement and a decade-long healthcare connection between the two countries. Dr. GSK Velu had the opportunity to interact with and be photographed alongside Prime Minister Narendra Modi, President Guy Parmelin and Mrs. Dominique Parmelin. It was a memorable moment that reflected the possibilities of deeper India-Switzerland collaboration.
Dr. GSK Velu's Interaction with Narendra Modi and Swiss President Guy Parmelin
The luncheon celebrated the relationship between India and Switzerland, with discussions and engagements reflecting the potential for stronger bilateral cooperation. Dr. GSK Velu's participation offered an opportunity to engage with the distinguished dignitaries and be part of an important diplomatic occasion.
The gathering also showcased Indian hospitality through a carefully curated selection of healthy and authentic Indian cuisine, which was appreciated by the visiting Swiss delegation.
For Dr. Velu, the interaction carried significance beyond the occasion itself. His professional association with Switzerland through Trivitron Healthcare's international operations has established a meaningful connection between Indian healthcare innovation and Swiss healthcare institutions.
Trivitron Healthcare's Contribution to Switzerland's National Newborn Screening Programme
One of the most significant connections between Trivitron Healthcare and Switzerland is its contribution to the country's National Newborn Screening Programme.
Since 2016, Trivitron Healthcare's wholly owned Finnish subsidiary, Labsystems Diagnostics Oy, has been supporting the programme at the University Children's Hospital Zurich. For the past decade, newborns across Switzerland have been screened using Labsystems' instruments, reagents and diagnostic solutions.
The programme's scale reflects the importance of this contribution:
- Approximately 85,000 newborns are screened every year.
- 11 serious congenital disorders are covered through the screening programme.
- 10 years of support from Labsystems Diagnostics Oy, since 2016.
Newborn screening plays an important role in identifying selected congenital disorders at an early stage, allowing healthcare professionals to initiate timely follow-up and intervention where required.
Through Labsystems Diagnostics Oy, an Indian healthcare group has been contributing to this national healthcare initiative through its Finnish subsidiary. This decade-long association demonstrates how international collaboration and diagnostic technologies can support public health programmes across borders.
Strengthening India-Switzerland Healthcare Relations
India and Switzerland share opportunities for collaboration across several sectors, including healthcare, medical technology, advanced manufacturing, research and development. With the India-EFTA Trade and Economic Partnership Agreement (TEPA) opening avenues for closer economic engagement, the scope for cooperation in these areas continues to grow.
For the healthcare and MedTech industries, this creates opportunities to strengthen technology partnerships, encourage research and development, expand manufacturing capabilities and support innovation.
Dr. GSK Velu's interaction with Prime Minister Narendra Modi during President Guy Parmelin's visit also brought attention to the role Indian healthcare enterprises can play in international collaborations. Trivitron Healthcare's experience in Switzerland's newborn screening programme is one example of how expertise and technology can contribute to healthcare systems beyond national boundaries.
Building the Future of Global Healthcare Collaboration
The luncheon at Hyderabad House was more than a diplomatic occasion for Dr. G.S.K. Velu. It was also an opportunity to reflect on a decade of healthcare collaboration between India, Finland and Switzerland, and the possibilities that lie ahead.
As India and Switzerland look towards deeper engagement in healthcare, MedTech, advanced manufacturing and innovation, Trivitron Healthcare remains committed to contributing to global healthcare through technology and international partnerships.
The decade-long association with Switzerland's National Newborn Screening Programme stands as an important example of how cross-border collaboration can support early diagnosis and better healthcare outcomes for future generations.
Frequently Asked Questions
1. Who is Dr. GSK Velu?
Dr. G.S.K. Velu is the Chairman of Trivitron Healthcare and an Indian healthcare entrepreneur. He is known for his contributions to the medical technology and diagnostics industry through Trivitron Healthcare and its international operations.
2. When did Dr. GSK Velu meet Prime Minister Narendra Modi?
Dr. GSK Velu attended a luncheon hosted by Prime Minister Narendra Modi on October 5, 2026, at Hyderabad House, New Delhi. The luncheon was held in honour of Swiss President Guy Parmelin and Mrs. Dominique Parmelin.
3. What is Trivitron Healthcare's contribution to Switzerland's National Newborn Screening Programme?
Through its wholly owned Finnish subsidiary, Labsystems Diagnostics Oy, Trivitron Healthcare has supported Switzerland's National Newborn Screening Programme since 2016. Its instruments, reagents and diagnostic solutions are used at the University Children's Hospital Zurich to screen approximately 85,000 newborns annually for 11 serious congenital disorders.
4. What is the role of Labsystems Diagnostics Oy in newborn screening?
Labsystems Diagnostics Oy, Trivitron Healthcare's Finnish subsidiary, provides instruments, reagents and diagnostic solutions for Switzerland's National Newborn Screening Programme. Its contribution supports the screening of newborns for selected congenital disorders, enabling early identification and timely clinical follow-up.
5. What are the opportunities for India-Switzerland collaboration in healthcare and MedTech?
India and Switzerland have opportunities to strengthen collaboration in healthcare, medical technology, advanced manufacturing, research and development, and innovation. The India-EFTA Trade and Economic Partnership Agreement (TEPA) also creates opportunities for closer economic engagement and technology partnerships between the two regions.

